|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-24
|
|
pubmed:abstractText |
Uterine Papillary Serous Carcinoma (UPSC) is uncommon and accounts for less than 5% of all uterine cancers. Therefore the majority of evidence about the benefits of adjuvant treatment comes from retrospective case series. We conducted a prospective multi-centre non-randomized phase 2 clinical trial using four cycles of adjuvant paclitaxel plus carboplatin chemotherapy followed by pelvic radiotherapy, in order to evaluate the tolerability and safety of this approach.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
pubmed-author:BolzKatharinaK,
pubmed-author:CheukRobynR,
pubmed-author:GohJeffreyJ,
pubmed-author:JandaMonikaM,
pubmed-author:Kondalsamy-ChennakesavanSrinivasS,
pubmed-author:MileshkinLindaL,
pubmed-author:NicklinJames LJL,
pubmed-author:ObermairAndreasA,
pubmed-author:PerrinLewis CLC,
pubmed-author:SykesPeterP,
pubmed-author:VaseyPaulP,
pubmed-author:WyldDavidD
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
120
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
179-84
|
|
pubmed:meshHeading |
pubmed-meshheading:21126755-Adult,
pubmed-meshheading:21126755-Aged,
pubmed-meshheading:21126755-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21126755-Carboplatin,
pubmed-meshheading:21126755-Chemotherapy, Adjuvant,
pubmed-meshheading:21126755-Combined Modality Therapy,
pubmed-meshheading:21126755-Cystadenocarcinoma, Papillary,
pubmed-meshheading:21126755-Cystadenocarcinoma, Serous,
pubmed-meshheading:21126755-Female,
pubmed-meshheading:21126755-Humans,
pubmed-meshheading:21126755-Middle Aged,
pubmed-meshheading:21126755-Paclitaxel,
pubmed-meshheading:21126755-Prospective Studies,
pubmed-meshheading:21126755-Quality of Life,
pubmed-meshheading:21126755-Survival Analysis,
pubmed-meshheading:21126755-Uterine Neoplasms
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
|
|
pubmed:affiliation |
University of Queensland, Brisbane, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
